Apollomics (NASDAQ:APLM) Trading 1.8% Higher – What’s Next?

Apollomics Inc. (NASDAQ:APLM) shares shot up 1.8% during mid-day trading on Friday . The company traded as high as $14.79 and last traded at $14.25. 19,128 shares traded hands during trading, an increase of 125% from the average session volume of 8,505 shares. The stock had previously closed at $14.00.

Analyst Ratings Changes

Separately, Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics presently has an average rating of “Sell”.

Apollomics Stock Up 1.8%

The business has a fifty day moving average of $14.51 and a 200 day moving average of $17.29.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission (SEC). 19.13% of the stock is owned by institutional investors and hedge funds.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.